Novo Nordisk hands shelved Parkinson’s cell therapy to Zuckerberg-backed Cellular Intelligence
Novo will take an equity stake in Cellular Intelligence and is in line for future milestone payments and royalties. The startup plans to apply its AI platform to STEM-PD, a stem-cell-derived treatment Novo discontinued last October.
Novo Nordisk has handed over STEM-PD, an experimental stem-cell therapy for Parkinson’s disease, to Cellular Intelligence, an AI biotech backed by Mark Zuckerberg, the companies said on Monday.
Financial terms were not disclosed. Novo will take an equity stake in the startup and is eligible for future milestone payments and royalties. Novo discontinued the therapy last October when it shut down its cell-therapy unit during a broader restructuring.
STEM-PD is an allogeneic, stem-cell-derived treatment designed to replace dopamine-producing nerve cells lost in Parkinson’s disease. It had been in early clinical development at Novo before the unit was wound down.
Cellular Intelligence said it intends to use its proprietary AI platform to accelerate the...
Copyright of this story solely belongs to thenextweb.com. To see the full text click HERE
